Elemental EM: Myasthenia Gravis

This is the first post in the Elemental EM series, a rapid review of core emergency medicine topics. The goal is to present high yield facts as a foundation for practice and fundamentals for board review. Please enjoy the following bullet point summary on myasthenia gravis.


Author: Courtney Cassella, MD (@Corablacas, EM Resident Physician, Icahn SoM at Mount Sinai) // Edited by: Alex Koyfman, MD (@EMHighAK, EM Attending Physician, UT Southwestern Medical Center / Parkland Memorial Hospital) and Brit Long, MD (@long_brit)

Epidemiology/Pathophysiology

Source: http://www.myasthenia.asia/news.aspx?category=1
  • 0.15-0.7% of the population, Most often 3rd to 6th decade
  • Autoimmune: Acetylcholine receptor antibodies
    • Causes receptor degradation, dysfunction, and blockade
    • Impairs function at neuromuscular junction (NMJ) → decreased muscle strength
  • Dysfunction of thymus gland or immune response to infectious antigens → abnormal thymus → often thymoma present

Clinical Presentation

  • General weakness
    • Proximal muscles
    • Neck extensors
    • Facial or bulbar muscles: Ptosis, diplopia, dysphagia, dysarthria, dysphonia
  • Worsens: as the day progresses, with prolonged muscle use, hot temperatures, stress, infection
  • No deficit in sensory, reflex, or cerebellar function
  • Myasthenic crisis: Respiratory failure
    • Precipitants: infection, surgery, rapid tapering of immunosuppressants, pain, menstruation, pregnancy, sleep deprivation, medications
  • Evaluation for impending respiratory failure
    • Inspiratory function
      • Vital capacity <1L (<20-25 mL/kg)
      • Negative inspiratory force <20 cm H2O
      • Accessory muscle use
    • Expiratory function
      • Positive expiratory force <40 cmH2O
      • Weak cough
      • Difficulty counting to 20 in a single breath
    • Upper airway (bulbar) weakness: dysphagia, nasal regurgitation, nasal quality of speech, staccato speech, jaw weakness, bifacial paresis, tongue weakness

[table id=2 /]

Diagnosis

  • Serologic testing – acetylcholine receptor antibodies
  • Ice pack test – ptosis improves with ice pack application
  • Edrophonium or neostigmine (Acetylcholinesterase inhibitor) → improves muscle strength
    • Limited use in testing as may worsen weakness in other NMJ disorders or cholinergic crisis leading to respiratory failure.
    • Caution: cardiac disease → may cause bradycardia, AV block, atrial fibrillation, cardiac arrest
    • Differentiates myasthenic crisis versus cholinergic crisis
  • Electromyographic testing → postsynaptic NMJ dysfunction

Treatment

  • Neurology consult
Acetylcholinesterase Inhibitors (Adult Dosing)
Pyridostigmine Neostigmine
  • PO 60 – 90 mg every 4 hours
  • IV slow infusion 1/30th PO dose (2-3mg)
  • If a dose is missed, next dose is doubled
  • PO 15 mg
  • IV 0.5 mg
  • IM/SC 0.5 to 2.0 mg, onset 30 min, effect 4 hrs
  • Management of respiratory failure
    • Induction with smaller doses: Etomidate, fentanyl, propofol
    • Avoid use of depolarizing or nondepolarizing paralytic agents
      • If paralytics are necessary → half-dose
    • Immunosuppression: steroids, azathioprine, mycophenolate, plasma exchange, IVIG
    • Thymectomy

Resources/References

Share This:

Leave a Comment

Your email address will not be published. Required fields are marked *

emDOCs subscribes to the Free Open Access Meducation (FOAMed) initiative. Our goal is to inform the global EM community with timely and high-yield content about what providers like YOU are seeing and doing daily in your local ED.

WRITE FOR EMDOCS

We are actively recruiting both new topics and authors.
This project is rolling and you can submit an idea or write-up anytime!
Contact us at editors@emdocs.net

news, headlines, newsletter

Join our Newsletter

Keep up to date on all of the latest new articles, studies, and Podcasts.
Men’s only search engine mr.